全文获取类型
收费全文 | 3255篇 |
免费 | 222篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 86篇 |
妇产科学 | 126篇 |
基础医学 | 327篇 |
口腔科学 | 105篇 |
临床医学 | 469篇 |
内科学 | 718篇 |
皮肤病学 | 46篇 |
神经病学 | 155篇 |
特种医学 | 327篇 |
外科学 | 495篇 |
综合类 | 64篇 |
一般理论 | 22篇 |
预防医学 | 230篇 |
眼科学 | 18篇 |
药学 | 111篇 |
中国医学 | 5篇 |
肿瘤学 | 163篇 |
出版年
2021年 | 36篇 |
2020年 | 28篇 |
2019年 | 50篇 |
2018年 | 71篇 |
2017年 | 38篇 |
2016年 | 58篇 |
2015年 | 56篇 |
2014年 | 79篇 |
2013年 | 84篇 |
2012年 | 140篇 |
2011年 | 144篇 |
2010年 | 111篇 |
2009年 | 119篇 |
2008年 | 136篇 |
2007年 | 116篇 |
2006年 | 134篇 |
2005年 | 128篇 |
2004年 | 123篇 |
2003年 | 105篇 |
2002年 | 110篇 |
2001年 | 78篇 |
2000年 | 71篇 |
1999年 | 76篇 |
1998年 | 74篇 |
1997年 | 74篇 |
1996年 | 78篇 |
1995年 | 74篇 |
1994年 | 54篇 |
1993年 | 59篇 |
1992年 | 47篇 |
1991年 | 56篇 |
1990年 | 64篇 |
1989年 | 81篇 |
1988年 | 65篇 |
1987年 | 72篇 |
1986年 | 82篇 |
1985年 | 60篇 |
1984年 | 42篇 |
1983年 | 32篇 |
1982年 | 31篇 |
1981年 | 30篇 |
1980年 | 23篇 |
1979年 | 31篇 |
1978年 | 25篇 |
1977年 | 27篇 |
1976年 | 26篇 |
1975年 | 32篇 |
1974年 | 19篇 |
1973年 | 23篇 |
1972年 | 18篇 |
排序方式: 共有3485条查询结果,搜索用时 15 毫秒
1.
2.
M. Manfredi M. J. McCullough Z. M. Al‐Karaawi P. Vescovi S. R. Porter 《Molecular oral microbiology》2006,21(6):353-359
To increase our understanding of Candida pathogenicity, the identification of those strains most frequently associated with infections is of paramount importance. Polymerase chain reaction (PCR)‐based methods are extremely effective in differentiating and determining reproducibility, they require minimum starting material and are rapid and simple to perform. In this study, the genetic relatedness of Candida albicans was assessed for two geographically different patient groups (London, UK and Parma, Italy) affected by diabetes mellitus. C. albicans samples from the oral cavities of non‐diabetic healthy subjects were also examined by PCR fingerprinting to evaluate the possible genetic differences among endogenous strains in individuals with and without diabetes mellitus. PCR fingerprinting, with subsequent phylogenetic analysis of C. albicans isolates from the diabetic patients from London and Italy and from the non‐diabetic subjects, revealed that there were significant differences (P < 0.0001) between C. albicans isolates indicative of the distinct ecological niches that occur in the oral cavities of these patient cohorts. The most diverse group comprised the isolates from the diabetic patients in the UK, possibly reflecting the antifungal treatment that these patients had received. Further studies that include isolates from patient cohorts with systemic diseases other than diabetes mellitus, and from more diverse geographic localities are required to explain the relatedness of C. albicans isolates in the mouth. 相似文献
3.
T. M. Egan S. Murray R. T. Bustami T. H. Shearon K. P. McCullough L. B. Edwards M. A. Coke E. R. Garrity S. C. Sweet D. A. Heiney F. L. Grover 《American journal of transplantation》2006,6(5P2):1212-1227
This article reviews the development of the new U.S. lung allocation system that took effect in spring 2005. In 1998, the Health Resources and Services Administration of the U.S. Department of Health and Human Services published the Organ Procurement and Transplantation Network (OPTN) Final Rule. Under the rule, which became effective in 2000, the OPTN had to demonstrate that existing allocation policies met certain conditions or change the policies to meet a range of criteria, including broader geographic sharing of organs, reducing the use of waiting time as an allocation criterion and creating equitable organ allocation systems using objective medical criteria and medical urgency to allocate donor organs for transplant. This mandate resulted in reviews of all organ allocation policies, and led to the creation of the Lung Allocation Subcommittee of the OPTN Thoracic Organ Transplantation Committee. This paper reviews the deliberations of the Subcommittee in identifying priorities for a new lung allocation system, the analyses undertaken by the OPTN and the Scientific Registry for Transplant Recipients and the evolution of a new lung allocation system that ranks candidates for lungs based on a Lung Allocation Score, incorporating waiting list and posttransplant survival probabilities. 相似文献
4.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
5.
6.
7.
8.
9.